Company** | University/Agency/ | Type Of | Product Area | Details (Month) |
Nonprofit [Scientist] | Agreement | |||
Advanced | The University of | Research | Development of nucleo- | Advanced Magnetics will |
Magnetics Inc. | Minnesota | collaboration | side therapeutics with | sponsor research over 3 years |
[Carston Wagner] | antiviral or antitumor | (7/98) | ||
characteristics | ||||
Advanced Tissue | The Massachusetts | License | Technology for growth | Advanced Tissue licensed |
Sciences Inc. | Institute of Tech- | of vascularized human | rights to 3 patents for use in | |
nology and Children's | tissues or organs on three- | broad range of tissues and | ||
Hospital, Boston | dimensional biocompatible, | organs (6/98) | ||
biodegradable and non- | ||||
biodegradable polymer | ||||
scaffolds in vivo | ||||
American | The National Institutes | Research | Evaluation of American | Preclinical research; use of |
Biogenetic | of Health (NIH) | collaboration | Biogenetic's drug ABS-103 | NIH's database to compare |
Sciences Inc. | (derivative of epilepsy drug | efficacy and toxicity of ABS- | ||
valproate) as therapy for | 103 to that of other existing | |||
epilepsy | and experimental epilepsy | |||
therapies (8/98) | ||||
The University of | Research | Development of assay that | State of Maryland, through | |
Maryland | collaboration | detects presence of anti- | Maryland Industrial Partner- | |
[Neil Constantine] | bodies to human herpes | ships agreement, will match | ||
virus type 8 | company's investment in | |||
project (8/98) | ||||
AntexBiologics | The National Institutes | License | Development of bacterial | Antex licensed rights to 7 |
(OTC Bulletin | of Health | and fungal carbohydrate | patents (10/98) | |
Board:ANTX) | receptor technologies for | |||
use in diagnostics and | ||||
therapeutics | ||||
Aurora | The University of | License | Specific covalent labeling | Aurora gets exclusive license |
Biosciences Corp. | California San Diego | of recombinant protein | (7/98) | |
[Roger Tsien] | molecules inside living | |||
cells (FLASH system; | ||||
involves fluorescent label) | ||||
AVI Biopharma | The University of | License | Telomere mimics (syn- | AVI Biopharma gets exclusive |
Inc. | Nebraska Medical School | thetic oligonucleotides) for | licenses to 9 issued patents, | |
treating cancer and other | 6 pending patent applications | |||
diseases; also, ultrasound | and 1 provisional patent appli- | |||
contrast agent (micro- | cation (8/98) | |||
bubbles coated with | ||||
albumin) to be used for | ||||
targeted drug delivery | ||||
Bio-Technology | Duke University | License | Polyethylene glycol (PEG) | Bio-Technology General licensed |
General Corp. | conjugates of recombi- | exclusive worldwide rights | ||
nant uricase to treat gout | to technology from Duke and | |||
and risk of kidney failure | Mountain View Pharmaceuti- | |||
cals Inc.; the latter will transfer | ||||
PEG technology to Bio-Tech- | ||||
nology General, which will | ||||
produce PEG-uricase conju- | ||||
gates, conduct clinical trials | ||||
and commercialize product; | ||||
partial funding provided by | ||||
the Israel-U.S. Binational | ||||
Industrial Research and Devel- | ||||
opment Foundation (8/98) | ||||
Biora AB | University of Texas | Two research | Identification of new | Each collaboration is for 3 |
(Sweden) | Health Science Center | collaborations | indications for Emdogain | years; further details ND (6/98) |
[David Cochran] | (protein-based gel for | |||
and University of | periodontal flap surgery); | |||
Ulm (Germany) | also, development of | |||
[Axel Spahr] | regenerative technologies | |||
for periodontal treatment | ||||
and oral surgery | ||||
Cell | The University of | License | Polyglutamic acid | Cell Therapeutics licensed |
Therapeutics Inc. | Texas M.D. Anderson | paclitaxel (water-soluble | rights to product; further details | |
Cancer Center | version of anticancer agent | ND (7/98) | ||
[Sidney Wallace; | paclitaxel) | |||
Chun Li] | ||||
Cel-Sci Corp. | Naval Research | Cooperative | Joint development of | CRADA is extension of 8/96 |
Institute of the | Research and | malaria vaccine via Cel- | research agreement (7/98) | |
U.S. Navy | Development | Sci's ligand epitope antigen | ||
Agreement | presentation technology | |||
(CRADA) | (LEAPS; combines T-cell | |||
binding ligand with disease- | ||||
associated peptide antigens) | ||||
Celsion Corp. | Duke University | Sponsored | Use of Celsion's thermo- | Celsion gets exclusive right to |
(OTC Bulletin | Medical Center | research | therapy system (heat-acti- | negotiate worldwide licenses to |
Board:CELN) | [Mark Dewhirst] | agreement | vated, lipid-based encapsu- | technology developed during |
lates) as activating | collaboration (6/98) | |||
mechanism for targeted | ||||
drug delivery, gene therapy | ||||
and anti-angiogenesis | ||||
systems | ||||
Cobequid Life | The Loeb Research | Sponsored | Continued development | ND (6/98) |
Sciences Inc. | Institute of Ottawa | research | of DNA vaccines for 2 | |
(VSE:KQR; | Hospital (Canada) | agreement | major emerging diseases | |
Canada) | [Heather Davis] | of farmed salmon | ||
Creative | The Miami Project to | Research | Use of Creative Bio- | 2-year collaboration; details ND |
BioMolecules Inc. | Cure Paralysis (the | collaboration | Molecule's morphogenic | (9/98) |
University of Miami | proteins (including OP-1) | |||
School of Medicine) | as therapies to enhance | |||
recovery after injury or | ||||
damage to brain or spinal | ||||
cord | ||||
Cyclacel Ltd.* | Centre National de | License | Penetratin (16 amino acid | Cyclacel gets exclusive world- |
(Scotland) | Recherche Scientifique | peptide that acts as cyto- | wide rights to product for use in | |
(CNRS; France) | plasmic and nuclear trans- | cancer (co-exclusive for cancers | ||
[Alain Prochiantz] | porter); Cyclacel will init- | of central nervous system), auto- | ||
ially use peptide in conjun- | immune, cardiovascular, derma- | |||
ction with its Pimetic drug | tologic and inflammatory dis- | |||
candidates (cell cycle con- | eases; CNRS gets up-front fee, | |||
trol peptide mimics) | milestones and royalties (7/98) | |||
Cytoclonal | The University of | License | Breast cancer peptide | Cytoclonal gets exclusive |
Pharmaceutics | California Los Angeles | inhibitors (target estrogen | worldwide rights; further | |
Inc. | [Richard Pietras] | receptors) | details ND (8/98) | |
Dendreon Corp.* | The Ludwig Institute | License | Use of Ludwig Institute's | ND (8/98) |
for Cancer Research | human tumor antigen | |||
NY-ESO-1 in Dendreon's | ||||
dendritic cell immuno- | ||||
therapy; initial targets are | ||||
prostate cancer and | ||||
multiple myeloma | ||||
Desmos Inc.* | The University of | Extension of | Use of extracellular matrix | Desmos will continue to fund |
California Los Angeles | research | protein laminin-5 as sub- | research; further details ND | |
[Yoko Mullen] | collaboration | strate for growth of human | (6/98) | |
pancreatic islet cells (insulin- | ||||
producing cells to trans- | ||||
plant into diabetics) | ||||
Diacrin Inc. | Massachusetts General | License | Immune system masking | Diacrin gets exclusive license; |
Hospital | technology for long-term | further details ND (7/98) | ||
[Denise Faustman] | acceptance of transplants; | |||
involves attachment of anti- | ||||
body molecule to surface of | ||||
donor cell; focus on treatment | ||||
of porcine brain cells prior to | ||||
transplantation into patients | ||||
with Parkinson's disease, | ||||
Huntington's disease and | ||||
focal epilepsy | ||||
diaDexus LLC | Cancer Research | License | Cervical cancer screening | diaDexus gets exclusive world- |
(joint venture | Campaign Technology | technology (details ND) | wide license to technology, | |
between Incyte | Ltd. (U.K.) | which it will develop and com- | ||
Pharmaceuticals | [Ron Laskey; | mercialize; terms ND (9/98) | ||
Inc. and Smith- | Nick Coleman; | |||
Kline Beecham plc; | Gareth Williams] | |||
NYSE:SBH; U.K.) | ||||
Digital Gene | University of Illinois | Research | Use of Digital Gene's | Institution gets fee-free access |
Technologies | at Chicago | collaboration | TOGA technology (total | to TOGA technology; Digital |
Inc.* | [Douglas Feinstein] | gene expression analysis) | Gene reserves rights to commer- | |
to isolate genes whose | cial applications of discoveries; | |||
expression will block | institution gets share of net | |||
inflammatory responses | revenue from commercialized | |||
of the brain to neuro- | products (6/98) | |||
pathies (dementia, | ||||
Alzheimer's disease), | ||||
infections and diseases | ||||
Indiana University | Research | Use of Digital Gene's | Institution gets fee-free access | |
School of Medicine | collaboration | TOGA technology (total | to TOGA technology; Digital | |
[Ting-Kai Li; | gene expression analysis) | Gene reserves rights to commer- | ||
Lucinda Carr] | to identify mRNAs that | cial applications of discoveries; | ||
are differentially expressed | institution gets share of net | |||
in rats carrying natural | revenue from commercialized | |||
genetic variants for | products (6/98) | |||
alcohol preference | ||||
(model for alcoholism) | ||||
The Jackson | Research | Use of Digital Gene's | Institution gets fee-free access | |
Laboratory | collaboration | TOGA technology (total | to TOGA technology; Digital | |
[Wayne Frankel; | gene expression analysis) | Gene reserves rights to commer- | ||
Gregory Cox] | to study gene expression | cial applications of discoveries; | ||
in mice carrying natural | institution gets share of net | |||
genetic variants (nmd and | revenue from commercialized | |||
Mnm genes) that either | products (8/98) | |||
enhance or suppress | ||||
degeneration of motor | ||||
neurons (model for | ||||
amyotrophic lateral | ||||
sclerosis) | ||||
Polish Academy of | Research | Use of Digital Gene's | Institution gets fee-free access | |
Sciences | collaboration | TOGA technology (total | to TOGA technology; Digital | |
[Ryszard Przewlocki] | gene expression analysis) | Gene reserves rights to commer- | ||
to study effect of morphine | cial applications of discoveries; | |||
on brain gene expression | institution gets share of net | |||
and to identify genes for | revenue from commercialized | |||
addiction | products (7/98) | |||
The Salk Institute for | Research | Use of Digital Gene's | Institution gets fee-free access | |
Biological Sciences | collaboration | TOGA technology (total | to TOGA technology; Digital | |
[Inder Verma] | gene expression analysis) | Gene reserves rights to commer- | ||
to study molecular basis | cial applications of discoveries; | |||
of oncogenesis; identifica- | institution gets share of net | |||
tion of genes regulated by | revenue from commercialized | |||
BRCA1 (functions as | products (8/98) | |||
tumor suppressor) | ||||
Digital Gene | The Salk Institute for | Research | Use of Digital Gene's | Institution gets fee-free access |
Technologies | Biological Sciences | collaboration | TOGA technology (total | to TOGA technology; Digital |
Inc. | [Carrolee Barlow] | gene expression analysis) | Gene reserves rights to commer- | |
to identify differentially | cial applications of discoveries; | |||
expressed genes in mouse | institution gets share of net | |||
model system for ataxia- | revenue from commercialized | |||
telangiectasia (Louis Bar | products (9/98) | |||
syndrome) | ||||
The Scripps Research | Research | Use of Digital Gene's | Institution gets fee-free access | |
Institute | collaboration | TOGA technology (total | to TOGA technology; Digital | |
[Francis Chisari] | gene expression analysis) | Gene reserves rights to commer- | ||
to identify cytokine-induced | cial applications of discoveries; | |||
antiviral proteins that cells | institution gets share of net | |||
infected with virus use to | revenue from commercialized | |||
destroy virus internally; | products (9/98) | |||
focus on chronic hepatitis | ||||
B virus infection | ||||
EntreMed Inc. | The National Cancer | Cooperative | Research to advance studies | This CRADA follows a letter of |
Institute (NCI) of the | Research and | on endostatin (naturally | intent signed in 8/97; 5-year | |
National Institutes of | Development | occurring fragment of | agreement; Entremed will | |
Health | Agreement | collagen XVIII; angiogenic | supply human endostatin pro- | |
[James Pluda] | (CRADA) | inhibitor) | tein to NCI for specific preclin- | |
ical pharmacology, toxicology | ||||
and clinical studies (9/98) | ||||
Eos | The Peter MacCallum | Research | Use of Eos' gene expression | Parties will combine Eos' tech- |
Biotechnology | Cancer Institute | collaboration | profiling and bioinformatics | nology with the Institute's |
Inc.* | (Australia) | capabilities to identify genes | access to clinical samples and | |
[Deon Venter] | with diagnostic, prognostic | tissue archives as well as mole- | ||
and therapeutic potential in | cular pathology (9/98) | |||
breast and colorectal cancer | ||||
Genome | Princeton University | License | Genes regulated by p53 | Genome Therapeutics gets |
Therapeutics | [Thomas Shenk] | tumor suppressor gene | exclusive license and retains | |
Corp. | right to sublicense or partner | |||
its oncology program; Princeton | ||||
gets license fee and royalties | ||||
(7/98) | ||||
Genta Inc. | The National Cancer | Cooperative | Development of Genta's | Parties signed letter of intent to |
Institute (NCI) of the | Research and | antisense compound G3139 | form a CRADA, under which | |
National Institutes of | Development | as anticancer agent; G3139 | they will collaborate in conduct- | |
Health | Agreement | targets BCL-2 gene (whose | ing clinical trials on G3139 | |
(CRADA) | overexpression inhibits | (6/98) | ||
apoptosis) | ||||
GlycoDesign | The Samuel Lunenfeld | License | Recombinant inhibitors of | GlycoDesign licensed patents; |
Inc.* (Canada) | Research Institute of | transforming growth factor | Lunenfeld Institute gets one- | |
Mount Sinai Hospital | beta (TGF-B; based on bind- | time payment plus royalties | ||
(Canada) | ing domain that regulates | (7/98) | ||
interaction of TGF-B with its | ||||
ligand) | ||||
HemaSure Inc. | The American Red | Strategic | Co-development of | Parties renewed alliance for 5 |
(OTC Bulletin | Cross | alliance | enhanced versions of Hema- | years, with option to extend for |
Board:HMSR) | Sure's leukoreduction filters | another 5 years (8/98) | ||
Hoechst-Ariad | Harvard School of | Research | Identification of genes that | Hoechst-Ariad has option on |
Genomics Center | Public Health | collaboration | regulate smooth muscle cell | exclusive license to any dis- |
(joint venture be- | [Arthur Lee] | differentiation and are thus | coveries (7/98) | |
tween Ariad | involved in atherosclerosis | |||
Pharmaceuticals | and angiogenesis | |||
Inc. and Hoechst | ||||
Marion Roussel Inc.) | ||||
Idun | Emory University | License | Use of apoptosis model | Idun gets exclusive license to |
Pharmaceuticals | [Xiaodong Wang] | system (which uses extracts | technology; further details ND | |
Inc.* | of normal cells) to screen | (8/98) | ||
for compounds that | ||||
inhibit or activate apop- | ||||
tosis | ||||
Igen | The Centers for | Cooperative | Development of rapid, | Igen will develop test via its |
International Inc. | Disease Control | Research and | non-microscopic test to | Origen technology; further |
Development | detect and quantify Crypto- | details ND (9/98) | ||
Agreement | sporidium parvum parasites | |||
(CRADA) | in drinking water and fecal | |||
samples | ||||
Incyte | Montefiori Medical | License | Use of defined hybrid- | Incyte gets exclusive license to |
Pharmaceuticals | Center | ization array to analyze | technology plus sublicensing | |
Inc. | [Leonard Augenlicht] | gene expression in diagnosis | rights; further details ND | |
and prognosis of disease, | (10/98) | |||
for disease risk evaluation | ||||
and to monitor effects of | ||||
drugs on gene expression | ||||
Introgen | Imperial Cancer | License | Use of tumor suppressor | Introgen gets exclusive option |
Therapeutics | Research Technology | gene PTEN in cancer gene | on license; Imperial Cancer gets | |
Inc.* | Ltd. (U.K.) | therapy; initially, combi- | up-front payment; if Introgen | |
nation with Introgen's | exercises option, Imperial Can- | |||
adenovirus-mediated gene | cer gets research funds, mile- | |||
delivery system for treat- | stones and royalties (6/98) | |||
ing prostate and brain | ||||
cancer | ||||
Ligand | The Salk Institute for | License | Non-peptide hormone | Ligand exercised its option for |
Pharmaceuticals | Biological Studies | 9-cis retinoic acid (active | an exclusive license; it paid a | |
Inc. | ingredient in Panretin Gel) | one-time fee of $4.1M for a | ||
fully paid-up license (5/98) | ||||
Medical Science | The University of | Research | Additional clinical trials | Research program will use |
Systems Inc. | North Carolina at | collaboration | on utility of Medical Sci- | University's database on risk |
Chapel Hill | ence Systems' genetic | factors (Atherosclerosis Risk | ||
[Steven Offenbacher; | susceptibility test for cor- | in the Community); no further | ||
James Beck; | onary heart disease | details (7/98) | ||
Gerardo Heiss] | ||||
Millennium | The University of | Clinical | Use of Millennium's | 3-year collaboration in 2 phases; |
Pharmaceuticals | Texas M.D. Anderson | collaboration | genomics technologies to | 1st phase focuses on collecting |
Inc. | Cancer Center | identify gene targets and | oncologic data from existing | |
[Robert Bast; Gabriel | markers for prognosis, | clinical samples and tissue col- | ||
Hortobagyi; Jordan | diagnosis and therapy of | lections; in 2nd phase, Millen- | ||
Gutterman; Waun-Ki | cancer; also, correlation | nium will help fund specific | ||
Hong; Gordon Mills] | of gene expression patterns | research programs and provide | ||
with chemotherapy | limited access to its technol- | |||
sensitivity/resistance | ogies in exchange for certain | |||
rights to inventions and dis- | ||||
coveries (8/98) | ||||
The University of | Clinical | Use of Millennium's | 3-year collaboration; Millen- | |
Pittsburgh | collaboration | genomics technologies to | nium gets access to Western | |
[Rajiv Dhir] | identify gene targets and | Pennsylvania Genitourinary | ||
markers for prognosis, | Tissue Bank for identification | |||
diagnosis and therapy of | of disease targets; Millennium | |||
major diseases | will provide financial support, | |||
opportunities for collaborative | ||||
research programs and limited | ||||
access to its technologies in | ||||
exchange for certain rights to | ||||
inventions and discoveries (8/98) | ||||
MitoKor Inc.* | The University of | Research | Mitochondrial and nuclear | Partnership established through |
California San | collaboration | genomics and proteomics | the Biotechnology Strategic | |
Francisco | research in Alzheimer's | Targets for Alliances in | ||
[Brad Gibson; | disease; use of mass spec- | Research Project (BioSTAR) | ||
Martin Shetlar] | trometry to study conse- | (6/98) | ||
quences of metabolic dys- | ||||
function and oxidative stress | ||||
OraPharma Inc.* | The University of North | Research | Treatments and diagnostics | OraPharma gets option on |
Carolina at Chapel Hill | collaboration | for oral diseases, especially | exclusive worldwide license to | |
[Ray Williams; | periodontal disease | all technology resulting from | ||
Steven Offenbacher] | program (9/98) | |||
Pacific | The National Cancer | Cooperative | Further clinical develop- | Parties will jointly develop |
Pharmaceuticals | Institute (NCI) of the | Research and | ment of company's | clinical plan, including certain |
Inc. (OTC Bulletin | National Institutes of | Development | chemosensitizing agent | studies to be funded and con- |
Board:PPHA) | Health | Agreement | O6 benzylguanine | ducted by NCI; company |
(CRADA) | retains right to conduct inde- | |||
pendent clinical studies (8/98) | ||||
Paracelsian Inc. | The Southern Research | Research | Animal experiments to | Southern Research will test |
Institute | collaboration | determine antitumor activ- | compounds in mice; if success- | |
[Robert Struck] | ity of series of traditional | ful, parties will collaborate on | ||
Chinese medicine herbal | isolation of key compounds and | |||
extracts | seek R&D funds (7/98) | |||
PathoGenesis | The Cystic Fibrosis | Product rights | TOBI (tobramycin solution | PathoGenesis acquired all |
Corp. | Foundation | for inhalation) for managing | rights to product and will make | |
cystic fibrosis patients with | payments to Foundation over | |||
Pseudomonas aeruginosa | next 2 years (6/98) | |||
PPL | The Roslin Institute | License | Nuclear transfer technology | PPL licensed exclusive world- |
Therapeutics plc | (Scotland) | for nutraceutical and thera- | wide rights to technology | |
(Scotland) | peutic protein production in | (6/98) | ||
milk of livestock and rabbits | ||||
Ribi Immuno- | The University of | License | Molecular adjuvant tech- | Ribi gets exclusive worldwide |
Chem Research | Nebraska | nology for use in immuno- | license to technology (6/98) | |
Inc. | [Sam Sanderson] | therapy of cancer and infect- | ||
ious diseases; involves class | ||||
of synthetic peptides that bind | ||||
to complement receptors | ||||
Ribozyme | Duke University | License | Use of ribozymes to repair | Ribozyme gets exclusive world- |
Pharmaceuticals | [Bruce Sullenger] | genetic defect in beta-globin | wide license to technology | |
Inc. | gene; for treating sickle-cell | (6/98) | ||
anemia | ||||
Select | Institut Curie and The | Research | Methods for targeting | Select Therapeutics will fund |
Therapeutics Inc. | Centre National de la | collaboration | dendritic cells for stimula- | research and gets option for |
(OTC Bulletin | Recherche Scientifique | ting immune response; tech- | exclusive worldwide license to | |
Board:SLPU) | (France) | nology based on expression | technology (6/98) | |
of receptor for verotoxin | ||||
(naturally occurring protein | ||||
produced by strains of | ||||
Escherichia coli that binds | ||||
to receptors on certain | ||||
tumor types) | ||||
Selective | The University of | License | Use of gene-activated | Selective Genetics gets exclu- |
Genetics Inc.* | Michigan | matrix technology to trans- | sive license to technology | |
[Jeffrey Bonadio; | fer genes into bone pro- | (7/98) | ||
Steven Goldstein] | genitor cells and tissue | |||
repair sites | ||||
Siga | The Ludwig Institute | Research | Immunotherapeutic | Parties will jointly own any |
Pharmaceuticals | for Cancer Research | collaboration | vaccines for melanoma, | technology developed in |
Inc. | breast, bladder and ovarian | collaboration (9/98) | ||
cancer; combination of | ||||
Siga's vaccine delivery | ||||
system with Ludwig | ||||
Institute's tumor antigens | ||||
Small Molecule | State University of New | Sponsored | Development and use of | Small Molecule Therapeutics |
Therapeutics Inc.* | York at Stony Brook | research | cell-based functional screen | will fund research in exchange |
agreement; | to identify signaling pro- | for option on exclusive license | ||
license | teins in nuclear factor | to any targets discovered | ||
kappa-B (NF-kB) | (6/98) | |||
activation pathway | ||||
StressGen | The University of | Research | Identification and optimi- | Multi-institution collaboration |
Biotechnologies | Miami; The University | collaboration | zation of small molecules | based on StressGen's 2/98 |
Corp. (Canada) | of Connecticut; Hartford | that modulate cellular | exclusive license for University | |
Hospital | production of stress | of Miami's discovery platform | ||
proteins; to promote cell | of heat shock transcription | |||
survival under conditions | factors (7/98) | |||
that cause tissue damage | ||||
Therion | The Ludwig Institute | License | Use of Ludwig Institute's | Therion will develop live |
Biologics Corp.* | for Cancer Research | human tumor antigen | recombinant pox virus vectors | |
NY-ESO-1 with Therion's | that incorporate ESO-1 gene; | |||
pox virus vectors to create | Therion gets exclusive option | |||
immunotherapeutics for | to license gene for this use; | |||
various cancers | Ludwig Institute will conduct | |||
1st clinical trials (9/98) | ||||
Tranzyme Inc.* | University of Alabama | License | Series of patents on | Tranzyme gets exclusive |
(UAB) Research | lentivirus vectors for | license to patents (9/98) | ||
Foundation | gene therapy; also, | |||
diagnostic assay for | ||||
HIV drug sensitivity | ||||
VaxGen Inc.* | The National Institute | Research | Research on immune | ND (8/98) |
of Allergy and Infectious | collaboration | responses induced by | ||
Diseases (NIAID) of | preventive AIDS vaccine | |||
the National Institutes | AIDSVAX (recombinant | |||
of Health | gp120-based vaccine; | |||
currently in North Ameri- | ||||
can Phase III trials); also | ||||
research on use of AIDS- | ||||
VAX in combination with | ||||
other vaccines being | ||||
studied by NIAID | ||||
Viragen Inc. and | America's Blood | Strategic | Supply of usable human | Viragen gets preferential access |
its wholly owned | Centers | alliance | leukocytes for manufactur- | to 100% of leukocyte supply for |
subsidiary Viragen | ing of Omniferon (alpha- | a minimum of 10 years; Blood | ||
USA Inc. | interferon) | center and its members have | ||
option of buying 13.6% of Viragen | ||||
USA's common stock on achieve- | ||||
ment of milestones (7/98) | ||||
The American | Supply | Supply of human leuko- | Long-term supply agreement | |
Red Cross | agreement | cytes for production of | for up to 15 years; further | |
Omniferon (alpha inter- | details ND (9/98) | |||
feron) and LeukoVax | ||||
Wisconsin | The University of | Research | Preclinical development of | ND (7/98) |
Genetics Inc. | Wisconsin-Madison | collaboration | monoterpenes (plant- | |
(subsidiary of | derived compounds) as | |||
Endorex Corp.) | anticancer drugs | |||
ZymeTx Inc. | Oklahoma Medical | License | Family of compounds for | ZymeTx acquired worldwide |
(NASDAQ: | Research Foundation | treating HIV infection; lead | rights to compounds (7/98) | |
ZMTX) | compound ZX-0851 believed | |||
to act by modifying HIV RNA | ||||
NOTES: | ||||
@ This chart covers the period between 5/28/98 and 10/26/98. For a chart that covers the period from 1/1/98 to 5/27/98, see the 6/15/98 issue of BioWorld Financial Watch. | ||||
ND = Not disclosed, reported and/or available; VSE = Vancouver Stock Exchange | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 13-14. |